Search
for

    Did you mean 5-alpha-reductase 2?
    GlossarySteroid 5 Alpha-Reductase 2

    enzyme converting testosterone to potent androgen dihydrotestosterone (DHT)

    Steroid 5 Alpha-Reductase 2 (also known as 5α-Reductase Type 2 or SRD5A2) is an enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen. This enzyme plays a crucial role in the development of male characteristics and is also implicated in conditions like male pattern baldness and benign prostatic hyperplasia.

    Related Terms

    Learn

    5 / 15 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Neem Oil

      natural substance from Neem tree with medicinal and pesticidal properties

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Mechanism of action of alfatradiol (17 alpha estradiol)

      in Research/Science  6 upvotes 1 year ago
      The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.
      Can I still save my hairline at age of 15?

      community Can I still save my hairline at age of 15?

      in General  532 upvotes 4 months ago
      A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.